A randomised clinical trial to determine the aesthetic outcomes of two designs of resin-retained bridge designs

niversity of Bristol0 个研究点目标入组 40 人开始时间: 2019年7月22日最近更新: 2021年4月12日

适应症

试验速览

暂无简介。

•1. Consent: Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form
•2. Compliance: Understands and is willing, able and likely to comply with all study procedures
•3. General Health: Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history on oral examination
•4. Oral Cavity, participants must:
•4.1 Have at least one missing tooth, bounded by teeth, which is a single unit in the front of the mouth, being either an incisor or canine (UR123 UL123 LR123 LL123).
•4.2 Have teeth that can be used as abutments (for attachment of the RRB) that are unrestored and without pathology
•4.3 Be able to accommodate a pontic tooth replacement restoration
•4.4 Have no more than mild tooth wear with Basic Erosive Wear Examination (BEWE) score of 1 or less (Bartlett et al 2008) with no history of parafunctional habits
•5. Have good oral hygiene with:
•5.1 Full mouth Turesky plaque index score <1 (Turesky et al 1970)
•5.2 Basic Periodontal Exam (BPE) scores of 0, 1, 2. With a maximum of one sextant with a score of 3.
•6. Aged 11 years or older

•1. Current or recurrent disease/dental pathology that could affect bridge treatment
•2. Bleeding disorders
•3. Immuno-compromised.
•4. Current or relevant previous history of serious, severe or unstable physical or psychiatric illness, or any medical disorder that may require treatment or make the participant unlikely to fully complete the study, or any condition that presents undue risk from the study products or procedures
•5. Known or suspected intolerance or sensitivity to the study materials (or closely related compounds) or any of their stated ingredients
•6. Any medication which in the investigators opinion may interfere with the study
•7. Participation in another clinical study or receipt of an investigational drug within 10 days of the screening visit
•8. Recent history of alcohol or other substance abuse
•9. Any patient who, in the judgement of the investigator, should not participate in the study

发起方

niversity of Bristol